ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,702.55
-0.19%
US Tech 100
19,297.60
0.00%
Dow Jones
42,063.36
0.09%
Brent Oil
73.985
0.14%
Bitcoin
63,526.06
-0.15%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. IGM Biosciences Inc (IGMS) Quote

IGM Biosciences Inc

IGM Biosciences Inc (IGMS)

NASDAQ
16.16
0.00
(0.00%)
Closed September 23 4:00PM
Delayed by 15 minutes
0.00
0.00
(0.00%)
After Hours: -
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
16.16
Bid
15.20
Ask
16.88
Volume
-
0.00 Day's Range 0.00
3.81 52 Week Range 22.50
Market Cap
958.59M
Previous Close
16.16
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
309,297
Shares Outstanding
59,318,669
Dividend Yield
-
PE Ratio
-3.89
Earnings Per Share (EPS)
-4.15
Revenue
2.13M
Net Profit
-246.42M

About IGM Biosciences Inc

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking ago... IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.igmbio.com
Headquarters
Dover, Delaware, USA
Founded
-
IGM Biosciences Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IGMS. The last closing price for IGM Biosciences was $16.16. Over the last year, IGM Biosciences shares have traded in a share price range of $ 3.81 to $ 22.50.

IGM Biosciences currently has 59,318,669 shares outstanding. The market capitalization of IGM Biosciences is $958.59 million. IGM Biosciences has a price to earnings ratio (PE ratio) of -3.89.

Ask ADVFN Intelligence (AI)

IGMS Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities

September 17 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

September 17 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

September 17 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

September 17 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

September 17 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

September 17 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

September 17 2024
Edgar (US Regulatory)

IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit

MOUNTAIN VIEW, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today...

September 10 2024
GlobeNewswire Inc.

Form 8-K - Current report

August 14 2024
Edgar (US Regulatory)

IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update

– Enrollment complete in aplitabart randomized colorectal cancer clinical trial; top-line PFS results expected by the end of 1Q25 – – Second dose cohort cleared in imvotamab rheumatoid arthritis...

August 14 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
13.625128.920055205912.534922.512.3583923017.08700848CS
45.6453.612167300410.5222.59.1832793714.96688867CS
129.31135.9124087596.8522.56.172130929711.76257753CS
265.8156.135265700510.3522.56.172131969110.16487787CS
528.9122.589531687.2622.53.813180939.36243103CS
156-58.53-78.363904137174.6976.23.8135266318.6770639CS
260-5.35-24.872152487221.511333.8127633830.42043498CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAGRAfrican Agriculture Holdings Inc
$ 0.15
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 63.87
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.93
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 9.75
(0.00%)
0
AACGATA Creativity Global
$ 0.5103
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.15
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 63.87
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.93
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 9.75
(0.00%)
0
AACGATA Creativity Global
$ 0.5103
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.15
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 63.87
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.93
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 9.75
(0.00%)
0
AACGATA Creativity Global
$ 0.5103
(0.00%)
0

IGMS Discussion

View Posts
Monksdream Monksdream 3 months ago
IGMS under $10
👍️0
Monksdream Monksdream 5 months ago
IGMS under $10
👍️0
crudeoil24 crudeoil24 2 years ago
Truist Reiterates Buy Rating, $80 Price Target.
👍️0
crudeoil24 crudeoil24 2 years ago
Let's see if IGMS gets FDA phase I,II,III, approvals . Sanofi believes it'll happen.
👍️0
crudeoil24 crudeoil24 2 years ago
14M float!
👍️0
crudeoil24 crudeoil24 2 years ago
Tons of cash going forward > IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell $200.0 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, non-voting common stock, in an underwritten public offering. In addition, IGM intends to grant the underwriters a 30-day option to purchase up to an additional $30.0 million of shares at the public offering price, less underwriting discounts and commissions. All of the securities offered in the offering will be sold by IGM. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
J.P. Morgan, BofA Securities, Stifel, and Guggenheim Securities are acting as joint book-running managers for the offering.
👍️0
TheFinalCD TheFinalCD 2 years ago
https://ih.advfn.com/stock-market/NASDAQ/igm-biosciences-IGMS/stock-news/87682546/igm-announces-proposed-public-offering

https://www.wsgr.com/print/v2/content/185066/Firm-Advises-IGM-Biosciences%2C-Inc.-on-%24230-Million-Public-Offering.pdf
👍️0

Your Recent History

NASDAQ
IGMS
IGM Biosciences
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved